Example Validation Master Plan | IVT - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Example Validation Master Plan | IVT

IVT

Validation Week
SPOTLIGHT EVENT

IVT’s 19th Annual
Validation Week

October 22-24, 2013
San Diego, California

Brochure | Register

RELATED ARTICLES

More in GMPs/Validation

Tim Fields
Example of process validation life cycle

This Validation Master Plan serves as a summary of the overall strategy for the validation of a facility. This Validation Master Plan provides an overview of the each process and describes the validation approach along with supporting validation rationale.

This VMP addresses the all activities related to equipment, utilities, processes, systems, and procedures that may impact the product quality.  Specific systems, equipment, utilities, and procedures to be qualified and processes to be validated shall be determined based on documented risk assessment.

The purpose of the validation plan is to demonstrate that the critical equipment, systems, and processes perform as designed and intended.  All validation will be conducted prospectively following written and approved protocols.  Change control and qualification of equipment and systems will be conducted in a manner consistent with a company's policies and procedures.  Specific equipment, systems, and processes to be validated will be determined based on a documented risk assessment.  

Download the example Validation Master Plan.

Download the accompanying presentation "Writing Effective Validation Protocols and Validation Master Plans," from IVT's 15th Annual Validation Week, Philadelphia, PA, October 2009.

This article was originally published for IVT - read article on IVT here: Example Validation Master Plan | IVT.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: IVT,
Click here